Fig. 6.

GSTP and PKM2 expression are increased in HDM-exposed BALF and in sputum of people with asthma with high levels of IL-1ß and lactate and correlates with disease severity. A, Representative western blots of extracellular GSTP and PKM2 in BALF from HDM-exposed WT and Gstp^−/- mice. B, Representative western blots of extracellular GSTP and PKM2 from induced sputum samples of 4 healthy subjects (HS), 4 participants with asthma (AL) with low sputum IL-1β (<20 pg/mL) and low sputum lactate levels (<33 μM), and 4 participants with asthma (AH) with high sputum IL-1β (>30 pg/mL) and sputum lactate (>80 μM) levels. Each lane represents an individual participant. C, Quantification of GSTP (left) and PKM2 (right) immunoreactivity from 20 HS, AL and AH subjects. Individual western blots of GSTP and PKM2 from the additional 16 HS, AL, and AH subject are shown in Fig. S5. D, Spearman correlation analysis of bronchial brushings transcriptomics, sputum transcriptomics and sputum proteomics datasets, derived from the U-BIOPRED cohort. Shown are Rho and p values of the correlations between glycolysis and PKM2, glycolysis and GSTP, as well as PKM2 and GSTP. E, Figure showing the correlation between GSTP and PKM2 in patients of the different datasets: bronchial brushing transcriptomics (left), sputum transcriptomics (middle), and sputum proteomics (right). HV: healthy volunteers, MMA: mild/moderate non-smoking asthma subjects, SA.ns: severe non-smoking participants with asthma, SA.S: current/ex-smokers with severe asthma. *p < 0.05 analyzed by one-way ANOVA with Tukey's multiple comparisons test.